These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8640699)

  • 21. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
    Morgan LR
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
    J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
    Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
    Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
    Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer.
    Falkson CI; Falkson HC
    Ann Oncol; 1996 Jul; 7(5):465-9. PubMed ID: 8839900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
    J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical trial of fadrozole hydrochloride for postmenopausal patients with recurrent breast cancer].
    Kanzaki M; Nakaya Y; Kojima K; Toda H; Tobayama S; Machida H; Ohba M
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):959-65. PubMed ID: 10396324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
    Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
    Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Supportive treatment with megestrol acetate during radio(chemo)therapy in patients with tumors in the head-neck area. A randomized study].
    Fietkau R; Riepl M; Kettner H; Hinke A; Sauer R
    Strahlenther Onkol; 1996 Mar; 172(3):162-8. PubMed ID: 8721265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.
    Bonomi P; Pessis D; Bunting N; Block M; Anderson K; Wolter J; Rossof A; Slayton R; Harris J
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):36-9. PubMed ID: 3975650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.
    Pritchard KI
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4356s-4359s; discussion 4411s-4412s. PubMed ID: 11916225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
    J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study].
    Tominaga T; Abe O; Asaishi K; Abe R; Enomoto K; Kajiwara T; Yoshida M; Wada T; Nomura Y
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):465-75. PubMed ID: 8129387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Introduction of a new aromatase inhibitor fadrozole hydrochloride hydsate].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1991-7. PubMed ID: 7487133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
    Raats JI; Falkson G; Falkson HC
    J Clin Oncol; 1992 Jan; 10(1):111-6. PubMed ID: 1530798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
    Tanaka M; Yano S; Hasegawa Y; Nakao K
    Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.